Publications by authors named "Gilberto Lopes Junior"
Context: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events.
Objective: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms.
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study.
Sao Paulo Med J
May 2020
Article Synopsis
- - Lung cancer is a prevalent issue in Brazil, where advancements in targeted treatments like EGFR have not been widely implemented in public healthcare, limiting patient access to effective therapies.
- - A study assessing the economic and social impact of adopting EGFR-targeted therapy within Brazil's public healthcare system found no survival benefits and identified 1,556 potential life-years lost annually, with significant budget implications ranging from 48 to 125 million BRL depending on the drug.
- - Implementing strategies to reduce drug costs, such as acquisition discounts or fixed pricing, could enhance access to these therapies for lung cancer patients in Brazil.
The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011.
Einstein (Sao Paulo)
October 2015
Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment.
Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature.